CO2023018652A2 - Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos - Google Patents
Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estosInfo
- Publication number
- CO2023018652A2 CO2023018652A2 CONC2023/0018652A CO2023018652A CO2023018652A2 CO 2023018652 A2 CO2023018652 A2 CO 2023018652A2 CO 2023018652 A CO2023018652 A CO 2023018652A CO 2023018652 A2 CO2023018652 A2 CO 2023018652A2
- Authority
- CO
- Colombia
- Prior art keywords
- analogues
- fluorinated
- methods
- tryptamine compounds
- tryptamine
- Prior art date
Links
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical class C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195943P | 2021-06-02 | 2021-06-02 | |
| US202163288313P | 2021-12-10 | 2021-12-10 | |
| PCT/US2022/032000 WO2022256554A1 (en) | 2021-06-02 | 2022-06-02 | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023018652A2 true CO2023018652A2 (es) | 2024-01-25 |
Family
ID=84324579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0018652A CO2023018652A2 (es) | 2021-06-02 | 2023-12-29 | Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240286998A1 (https=) |
| EP (1) | EP4347559A4 (https=) |
| JP (1) | JP2024523822A (https=) |
| KR (1) | KR20240017363A (https=) |
| AU (1) | AU2022287013A1 (https=) |
| BR (1) | BR112023025340A2 (https=) |
| CA (1) | CA3220850A1 (https=) |
| CO (1) | CO2023018652A2 (https=) |
| IL (1) | IL308944A (https=) |
| MX (1) | MX2023014437A (https=) |
| WO (1) | WO2022256554A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| US20250091993A1 (en) * | 2022-01-27 | 2025-03-20 | Terran Biosciences Inc. | Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12180158B1 (en) | 2023-08-03 | 2024-12-31 | Gilgamesh Pharmaceuticals, Inc. | Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine |
| WO2025052388A1 (en) * | 2023-09-07 | 2025-03-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Psychedelic compounds, methods of their preparation and uses thereof |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2223239A1 (en) * | 1995-06-06 | 1996-12-12 | Schering Corporation | Substituted benzene-fused hetero- and carbocyclics as neurokinin antagonists |
| DE19615232A1 (de) * | 1996-04-18 | 1997-10-23 | Merck Patent Gmbh | Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
| US6800637B2 (en) * | 2002-09-12 | 2004-10-05 | Wyeth | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines |
| CA3052974A1 (en) * | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| EP3793360A4 (en) * | 2018-05-16 | 2022-02-16 | University of Florida Research Foundation | Methods and compositions for substituted 2,5-diketopiperazine analogs |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| BR112022015379A2 (pt) * | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| KR20260008838A (ko) * | 2020-02-18 | 2026-01-16 | 길가메쉬 파마슈티컬스, 인코포레이티드 | 기분 장애 치료에 사용되기 위한 특이적 트립타민 |
| AU2021337466A1 (en) * | 2020-09-01 | 2023-03-30 | Enveric Biosciences Canada Inc. | Halogenated psilocybin derivatives and methods of using |
| AU2021343525A1 (en) * | 2020-09-20 | 2023-05-18 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
| JP2023553094A (ja) * | 2020-12-07 | 2023-12-20 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性薬としての３位環－アミンインドール誘導体 |
-
2022
- 2022-06-02 US US18/565,565 patent/US20240286998A1/en active Pending
- 2022-06-02 CA CA3220850A patent/CA3220850A1/en active Pending
- 2022-06-02 AU AU2022287013A patent/AU2022287013A1/en active Pending
- 2022-06-02 BR BR112023025340A patent/BR112023025340A2/pt unknown
- 2022-06-02 IL IL308944A patent/IL308944A/en unknown
- 2022-06-02 EP EP22816868.8A patent/EP4347559A4/en active Pending
- 2022-06-02 KR KR1020237044652A patent/KR20240017363A/ko active Pending
- 2022-06-02 JP JP2023574858A patent/JP2024523822A/ja active Pending
- 2022-06-02 MX MX2023014437A patent/MX2023014437A/es unknown
- 2022-06-02 WO PCT/US2022/032000 patent/WO2022256554A1/en not_active Ceased
-
2023
- 2023-12-29 CO CONC2023/0018652A patent/CO2023018652A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347559A4 (en) | 2025-04-09 |
| IL308944A (en) | 2024-01-01 |
| CA3220850A1 (en) | 2022-12-08 |
| KR20240017363A (ko) | 2024-02-07 |
| BR112023025340A2 (pt) | 2024-02-20 |
| MX2023014437A (es) | 2024-03-08 |
| EP4347559A1 (en) | 2024-04-10 |
| JP2024523822A (ja) | 2024-07-02 |
| US20240286998A1 (en) | 2024-08-29 |
| WO2022256554A1 (en) | 2022-12-08 |
| AU2022287013A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023018652A2 (es) | Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos | |
| MX2023008453A (es) | Metodos de tratamiento para el abuso de sustancias. | |
| CL2019003800A1 (es) | Métodos para tratar la enfermedad de huntington. | |
| UY39135A (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| CL2019002574A1 (es) | Moduladores de la expresión de pcsk9. | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| CO2021008816A2 (es) | Moduladores de trex1 | |
| MX2021015545A (es) | Moduladores de cot y metodos de uso de estos. | |
| CL2020003447A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
| CO2020015377A2 (es) | Moduladores de la expresión de apol1 | |
| MX2019000428A (es) | Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori. | |
| CO2020008769A2 (es) | Moduladores de la expresión dnm2 | |
| CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
| CL2020002101A1 (es) | Formulaciones de liberación sostenida de ácido bempedoico. | |
| CL2018001407A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| MX2024002913A (es) | Anticuerpos anti-siglec-6 y metodos de uso de los mismos. | |
| CL2020001252A1 (es) | Métodos de uso y composiciones que contienen dulaglutida. | |
| PE20221009A1 (es) | Sintesis de un inhibidor de calicreina plasmatica a escala de proceso | |
| CL2024000881A1 (es) | Estructuras derivadas de tn3 específicas de cd40l para tratamiento y prevención del síndrome de sjogren | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| CO2022013603A2 (es) | Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| MX2022005354A (es) | Uso de un inhibidor de la cinasa janus y un inhibidor de la telomerasa para el tratamiento de neoplasias mieloproliferativas. | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac |